Literature DB >> 24877605

The role of formulation on the pharmacokinetics of antiretroviral drugs.

Diane E T Bastiaans1, Tim R Cressey, Herman Vromans, David M Burger.   

Abstract

INTRODUCTION: A multitude of antiretroviral drug formulations are now available for HIV-infected adults and children. These formulations include individual and co-formulated drugs, many of which are also supplied in generic versions. Many antiretroviral drugs have a low aqueous solubility and poor bioavailability. Drug formulation can significantly affect bioavailability, and given the increasing number of new formulations and drug combinations, it is important to be aware that formulation can influence the pharmacokinetics of antiretroviral drugs. AREAS COVERED: This review provides an overview of studies assessing the pharmacokinetics of different antiretroviral drug formulations in adults and children, including fixed-dose combinations. For some antiretroviral drugs, differences in pharmacokinetics have been described, with largest differences in exposure when a liquid formulation is compared to a tablet or capsule formulation. Biopharmaceutical properties of antiretroviral drugs relevant to bioavailability are discussed. EXPERT OPINION: Antiretroviral drug formulations and their excipients can significantly impact drug exposure. However, this is not yet fully recognized. It is important to realize that children use different formulations than adults. Effort should be made to ensure that adequate drug exposures are achieved to treat HIV-infected children. In addition, manipulation of drug formulations may lead to differences in pharmacokinetics.

Entities:  

Keywords:  antiretroviral therapy; bioequivalence; biopharmaceutics; child; formulation; pharmacokinetics

Mesh:

Substances:

Year:  2014        PMID: 24877605     DOI: 10.1517/17425255.2014.925879

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  7 in total

1.  Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.

Authors:  Esther J H Janssen; Diane E T Bastiaans; Pyry A J Välitalo; Annemarie M C van Rossum; Evelyne Jacqz-Aigrain; Hermione Lyall; Catherijne A J Knibbe; David M Burger
Journal:  Br J Clin Pharmacol       Date:  2017-02-14       Impact factor: 4.335

2.  Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate.

Authors:  Darren M Moss; Paul Domanico; Melynda Watkins; Seonghee Park; Ryan Randolph; Steve Wring; Rajith Kumar Reddy Rajoli; James Hobson; Steve Rannard; Marco Siccardi; Andrew Owen
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 3.  The Need for Pediatric Formulations to Treat Children with HIV.

Authors:  Adrienne F Schlatter; Andrew R Deathe; Rachel C Vreeman
Journal:  AIDS Res Treat       Date:  2016-06-16

Review 4.  The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection.

Authors:  Anna Halling Folkmar Andersen; Martin Tolstrup
Journal:  Viruses       Date:  2020-04-07       Impact factor: 5.048

Review 5.  Innovations in Pediatric Drug Formulations and Administration Technologies for Low Resource Settings.

Authors:  Stephen E Gerrard; Jennifer Walsh; Niya Bowers; Smita Salunke; Susan Hershenson
Journal:  Pharmaceutics       Date:  2019-10-08       Impact factor: 6.321

6.  Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.

Authors:  Paolo Denti; Anneke C Hesseling; Anthony J Garcia-Prats; Susan E Purchase; Muhammad Osman; Heather R Draper; H Simon Schaaf; Lubbe Wiesner
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

7.  Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open-Label, Randomized Study.

Authors:  Kimberly Adkison; Allen Wolstenholme; Yu Lou; Zhiping Zhang; Amy Eld; Teodora Perger; Harald Vangerow; Katy Hayward; Mark Shaefer; Cynthia McCoig
Journal:  Clin Pharmacol Ther       Date:  2017-12-11       Impact factor: 6.875

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.